InventVacc Biologicals
Developer and manufacturer of vaccines and vaccine-related biologics. Focus areas include conjugate vaccine development, process and analytical development for protein-based vaccines, clinical- and commercial-scale manufacturing, automation and electronic data management for manufacturing operations, and market access/localization in multiple global regions. The organization has participated in licensing and manufacturing activities for a Haemophilus influenzae type a (Hia) glycoconjugate vaccine and publishes preclinical and development updates.
Industries
Nr. of Employees
small (1-50)
InventVacc Biologicals
Vancouver, British Columbia, Canada, North America
Products
Haemophilus influenzae type a (Hia) glycoconjugate vaccine (pipeline)
A glycoconjugate vaccine candidate targeting Haemophilus influenzae serotype a (Hia) intended to prevent invasive Hia disease; listed in a development pipeline with discovery, preclinical and early-phase clinical stages.
Haemophilus Influenza Type A (Hia) : IVIV 378
A pediatric and adolescent conjugate vaccine candidate targeting Haemophilus Influenza Type A (Hia) currently in the discovery phase.
Haemophilus influenzae type a (Hia) glycoconjugate vaccine (pipeline)
A glycoconjugate vaccine candidate targeting Haemophilus influenzae serotype a (Hia) intended to prevent invasive Hia disease; listed in a development pipeline with discovery, preclinical and early-phase clinical stages.
Haemophilus Influenza Type A (Hia) : IVIV 378
A pediatric and adolescent conjugate vaccine candidate targeting Haemophilus Influenza Type A (Hia) currently in the discovery phase.
Services
Commercialization and localization of biologics across multiple global regions with local partner networks and exploration of local manufacturing opportunities.
Process and analytical development support for protein-based vaccine processes to improve product quality, yields and reduce cycle times in compliance with phase-appropriate regulatory guidelines.
Design and implementation of automation strategies for manufacturing, integrated process train design to support continuous manufacturing and automated data collection for observability and monitoring.
Manufacturing services spanning clinical supply through commercial production with defined process flows, product traceability and continuous monitoring of manufacturing and logistics data.
Commercialization and localization of biologics across multiple global regions with local partner networks and exploration of local manufacturing opportunities.
Process and analytical development support for protein-based vaccine processes to improve product quality, yields and reduce cycle times in compliance with phase-appropriate regulatory guidelines.
Design and implementation of automation strategies for manufacturing, integrated process train design to support continuous manufacturing and automated data collection for observability and monitoring.
Manufacturing services spanning clinical supply through commercial production with defined process flows, product traceability and continuous monitoring of manufacturing and logistics data.
Expertise Areas
- Vaccine development (conjugate vaccines)
- Bioprocess and scale-up
- Analytical development and immunogenicity testing
- Clinical trial enablement (early phase)
Key Technologies
- Glycoconjugation chemistry
- Cell culture and fermentation
- Protein purification
- Bioreactor/cell bank manufacturing
News & Updates
Announcement of a published original research article reporting preclinical immunogenicity studies for a Hia glycoconjugate vaccine (publication in Vaccine journal referenced).
Report on licensing and manufacturing activities related to a Hia vaccine developed by Canadian public agencies and licensed for manufacturing; describes process development including fermentation and conjugation to carrier protein.
Summary of work by public research organizations on Hia vaccine discovery and process development steps including strain selection, fermentation and conjugation chemistry; notes license for manufacturing.
Press coverage describing the Hia vaccine development and licensing for manufacturing, background epidemiology of Hia in northern and Indigenous communities, and plans for clinical trials.
Announcement of a published original research article reporting preclinical immunogenicity studies for a Hia glycoconjugate vaccine (publication in Vaccine journal referenced).
Report on licensing and manufacturing activities related to a Hia vaccine developed by Canadian public agencies and licensed for manufacturing; describes process development including fermentation and conjugation to carrier protein.
Summary of work by public research organizations on Hia vaccine discovery and process development steps including strain selection, fermentation and conjugation chemistry; notes license for manufacturing.
Press coverage describing the Hia vaccine development and licensing for manufacturing, background epidemiology of Hia in northern and Indigenous communities, and plans for clinical trials.